Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox 4 (DUX4) messenger RNA (mRNA) is the transcript of the DUX4 gene, which encodes a transcription factor that is normally expressed only during early embryonic development and is epigenetically silenced in adult somatic tissues. In patients with facioscapulohumeral muscular dystrophy (FSHD), genetic mutations lead to the failure of epigenetic suppression, resulting in the aberrant, toxic expression of DUX4 mRNA and protein in skeletal muscle. This ectopic expression triggers a cascade of downstream transcriptional changes that cause muscle fiber degeneration, oxidative stress, inflammation, and apoptosis.\n\nConsequently, DUX4 mRNA has emerged as a primary therapeutic target for disease-modifying treatments. Therapeutic strategies focus on sequence-specific knockdown of the transcript using RNA interference (RNAi) or antisense oligonucleotides (ASOs) to prevent the translation of the toxic DUX4 protein. Promising clinical-stage candidates, such as delpacibart braxlosiran (del-brax) and DYNE-302, utilize antibody-oligonucleotide conjugates (AOCs) targeting transferrin receptor 1 (TfR1) to deliver DUX4-specific small interfering RNAs (siRNAs) directly into skeletal muscle cells. These therapies aim to halt or reverse muscle wasting and improve functional mobility in patients with FSHD.
RNA interference (RNAi) or antisense knockdown leading to sequence-specific degradation of DUX4 mRNA, thereby preventing translation of the toxic DUX4 protein.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double homeobox 4 (DUX4) messenger RNA (DUX4 mRNA).